Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

740
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
740
What is Genetic Engineering?00:49

What is Genetic Engineering?

79.8K
Overview
79.8K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

261
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
261
Hepatic Portal System01:21

Hepatic Portal System

5.6K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.6K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

280
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
280
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

219
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
219

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

At the crossroads of senescence and immunosuppression: Machine learning and multi-omics unveil the central role of FAP in HNSCC.

Bioorganic chemistry·2026
Same author

Research on rural co-governance model under "micro-regeneration of community spaces" - a case study of Shanghai Pujiang country park.

Scientific reports·2026
Same author

Quantifying time-varying wind-driven effects on matched-field localization: Mechanisms and a physics-coupled Bayesian approacha).

The Journal of the Acoustical Society of America·2026
Same author

Stellar feedback drives the baryon deficiency in low-mass galaxies.

Science advances·2026
Same author

Altered thalamic subregional connectivity with default mode and frontoparietal networks in adolescents with depression.

Journal of affective disorders·2026
Same author

Regenerative potential of Schneiderian membrane-derived mesenchymal stem cells in sinus floor elevation model and calvarial defect model.

Journal of Zhejiang University. Science. B·2026

Related Experiment Video

Updated: Jan 23, 2026

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

1.9K

Engineered Perfusable Hepatic Fibrosis Model via Embedded Sacrificial Bioprinting Recapitulates Stiffness-Driven

Weikang Lv1,2, Tuya Naren1,2, Abdellah Aazmi1,2

  • 1State Key Laboratory of Fluid Power and Mechatronic Systems, Zhejiang University, Hangzhou, China.

Advanced Materials (Deerfield Beach, Fla.)
|January 22, 2026
PubMed
Summary
This summary is machine-generated.

This study developed a dynamic 3D liver fibrosis model with vascular networks. The model accurately replicates fibrosis progression and shows potential for testing liver fibrosis drugs.

Keywords:
dynamic mechanical force stimulationembedded sacrificial printinghepatic sinusoidsliver fibrosis model

More Related Videos

Microfluidic Bioprinting for Engineering Vascularized Tissues and Organoids
08:22

Microfluidic Bioprinting for Engineering Vascularized Tissues and Organoids

Published on: August 11, 2017

16.4K
Three-dimensional Patterning of Engineered Biofilms with a Do-it-yourself Bioprinter
08:40

Three-dimensional Patterning of Engineered Biofilms with a Do-it-yourself Bioprinter

Published on: May 16, 2019

10.2K

Related Experiment Videos

Last Updated: Jan 23, 2026

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

1.9K
Microfluidic Bioprinting for Engineering Vascularized Tissues and Organoids
08:22

Microfluidic Bioprinting for Engineering Vascularized Tissues and Organoids

Published on: August 11, 2017

16.4K
Three-dimensional Patterning of Engineered Biofilms with a Do-it-yourself Bioprinter
08:40

Three-dimensional Patterning of Engineered Biofilms with a Do-it-yourself Bioprinter

Published on: May 16, 2019

10.2K

Area of Science:

  • Biomedical Engineering
  • Regenerative Medicine
  • Pathophysiology

Background:

  • Hepatic fibrosis involves extracellular matrix (ECM) stiffening and hepatic stellate cell (HSC) activation.
  • Existing in vitro models lack engineered vasculature and dynamic mechanical stimulation.

Purpose of the Study:

  • To create a dynamically perfused 3D in vitro liver fibrosis model.
  • To investigate the impact of matrix stiffness and perfusion on HSC activation and hepatocyte function.
  • To establish a platform for evaluating anti-fibrotic therapies.

Main Methods:

  • Embedded sacrificial bioprinting to create vascular networks in tunable hydrogels.
  • Dynamic perfusion of 3D multicellular cultures.
  • Assessment of HSC activation and hepatocyte function under varying matrix stiffness and flow conditions.

Main Results:

  • Matrix stiffness directly drives HSC activation and myofibroblastic transdifferentiation.
  • Dynamic perfusion enhances hepatocyte sensitivity to stiff matrices, mimicking in vivo conditions.
  • Targeted inhibition partially reversed HSC activation and recovered liver function in the model.

Conclusions:

  • The developed model accurately recapitulates liver fibrosis pathophysiology.
  • This platform offers a promising approach for drug screening and therapeutic assessment for liver fibrosis.
  • Simultaneous integration of mechanical cues and vascularization is crucial for in vitro fibrosis modeling.